Eli Lilly (LLY) stock is in focus as the company posts detailed data from a late-stage trial for its obesity pill orforglipron at a European medical event. Read more here.
Eli Lilly posts detailed results from ATTAIN-1 late-stage trial for obesity pill
Sep. 17, 2025 7:07 AM ETEli Lilly and Company (LLY) StockNVO, NONOFBy: Dulan Lokuwithana, SA News Editor
Comments
(6)
Eli Lilly (NYSE:LLY) on Wednesday posted detailed d... [444 chars]